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a b s t r a c t
Purpose: Oral appliances (OAs) are commonly used as a noninvasive treatment for obstruc-
tive sleep apnea syndrome (OSAS). These devices are worn during sleep and create man-
dibular anterior traction to enlarge the upper airway. Continuous use of the device is
essential for the success of OA therapy, but some patients stop using the OA for various
reasons. The purpose of this research was to investigate complications in OA therapy that
might prevent continuous use of these devices.
Methods: The progress of 90 OSAS patients who visited Tokushima University Hospital and
underwent OA therapy was investigated with a mailed questionnaire. All patients had been
receiving OA therapy for more than 12 months.
Results: Forty patients responded to the questionnaire and of these, 22 were not wearing
their OA during sleep. The average period before stopping OA therapy was 9.6 months.
Answers from 38 patients who were treated with two-piece Herbst1 [1_TD$DIFF]-type oral appliances
were analyzed. The main reasons for stopping OA therapy were: (1) it was bothersome to
use; and (2) it did not effectively prevent sleep apnea. Comparison of OA complications
between current OA users and nonusers revealed significant differences for the items
‘‘difficulty sleeping’’ and ‘‘stifling feeling’’. OA users recorded better scores for sleep quality
than nonusers.
Conclusions: The results of this study indicate that patients discontinued OA therapy
because the appliance was ‘‘bothersome to use’’ and because it had ‘‘little or no effect’’
rather than because they experienced the typical complications of OA therapy.
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used to treat obstructive sleep apnea syndrome.1. Introduction
Obstructive sleep apnea (OSA) is a syndrome in which nasal
and oral airflow ceases in spite of continued diaphragmatic
efforts [1]. To prevent obstruction in the upper airway in this
syndrome, various approaches have been used, including
surgical, conservative, and instrumental therapy. These
approaches involve a variety of treatments such as tracheos-
tomy, surgery of the soft palate and oropharynx, reconstruc-
tive surgery of the facial skeleton, medications, weight
reduction, nasal continuous positive airway pressure (CPAP)
and oral appliance (OA) [2,3].
Because the effect of OSAS treatment without modification
of the upper airway morphology does not continue when the
patient stops treatment, continuous monitoring of the treat-
ment is required for it to succeed. Because OAs are typically
used for mild cases of sleep apnea, some of these patients
might beunaware of the symptomsand are not eager to receive
treatment. Undoubtedly, patient compliance for the treatment
is the primary requirement for continuous treatment. Patient
compliance is influenced by a number of factors. Symptoms
such as xerostomia, tooth and gingival pain, hypersalivation,
and temporomandibular andmyofascial discomfort are known
to be complications ofOA therapy [3–10]. If these complications
affect the continuation of OA therapy, such informationwill be
helpful for modifying the structure of OAs to increase the
continuous user ratio among OA therapy patients. The purpose
of this research was to investigate the continuous-use ratio of
OA therapy among OSAS patients through a questionnaire and
to examine the complications that might cause discontinua-
tion of OA therapy.2. Materials and methods
Ninety OSAS patients who visited the Department of General
Dentistryat [1_TD$DIFF] okushimaUniversityHospitalduring the10years
from 2004 to 2013 were invited to participate in the investiga-
tion. The inclusion criterion for this investigation was any
patient who had undergone OA therapy in this department
between 2004 and 2013.
All of these patients underwent sleep examinations at
medical hospitals for diagnosis of sleep apnea and were
referred to our clinic to receive OA therapy. A two-piece
Herbst1 bite-jumping OA (Ormco Corp., CA, USA) was
provided for most of these patients (Fig. 1) [11]. The maximum
range of frontal mandibular movement of each patient was
measured with a ruler and a 50–75% forward position from
intercuspationwas chosen as the tractivemandibular position
for the OA [12]. The degree of mandibular opening was set at
5 mm at the incisal point [13]. The clinical procedure for
occlusal registration for OA fabrication was described in a
previous report [14].
Questionnaires were mailed to these patients at least one
year after the start of OA therapy. The questionnaire included
questions about the continuous use of OA therapy, frequency
of OA use, period of total OA use, any complications with the
OA, reasons for stopping OA therapy if a nonuser, loudness of
snoring, daytime sleepiness, sleep sufficiency over the lastmonth, the Epworth Sleepiness Scale (ESS) [15], and the
Pittsburgh Sleep Quality Index (PSQI) [16].
Subjects were asked to grade their experience with
complications of OA, snoring and sleep quality as follows:
almost never: 0, sometimes: 1, frequently: 2, very frequently: 3,
unknown: NA. Apnea Hypopnea Index (AHI) of the subjects at
their initial visit was assessed from the medical records.
Then those subjects were separated into two groups: the
current OA user group, and the nonuser group who had
discontinued OA therapy. We compared the two groups using
theMann–WhitneyU test. ESS scores at the initial visit and the
follow-up visit were compared using the Wilcoxon signed-
rank test. To assess the correlations between the self-
evaluation for sleep quality and the follow up ESS scores,
Spearman’s rank correlation was performed. Statistical
analysis was performed with SPSS-15.0J for Windows (SPSS
Japan, Inc., Tokyo, Japan) and a 5% significance level was
adopted for analysis.
This research was approved by the Research Ethics
Committee of Tokushima University Hospital, [1_TD$DIFF] okushima,
Japan (No. 1149) and informed consent was taken from all
participating patients.3. Results
3.1. Respondent data
Forty patients out of 90 (44.4%) responded to the mailed
questionnaire (28 males and 12 females; average age,
57.8 years). Twenty-two (55.5%) of these respondents had
already stoppedOA therapy. The average period of OA therapy
for nonusers was 9.6 months (range, 2 weeks to 31 months).
The average period of therapy for the 18 current OA users was
34.4 months. The longest period of OA use was 6 years in this
investigation. About half of the OA users were wearing the OA
every night. Two patients (one current OA user and one
nonuser) had been fitted with amono block-type OA and were
excluded from the analysis. The other 38 patients had been
fitted with Herbst1[1_TD$DIFF] appliances (17 current OA users and
21 nonusers) as outlined in Fig. 2. The Herbst1 appliance
[(Fig._2)TD$FIG]
Fig. 2 – Flow diagram showing participant flow in this
investigation.
[(Fig._3)TD$FIG]
Fig. 3 – Comparison of the complications of OA therapy in
users and nonusers (*p < 0.05, **p < 0.01, Mann–Whitney U
test).
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movement, imposing fewer restrictions on patients than the
mono-block-type appliance [12]. Because this appliance
inhibits mouth breathing less than other appliances, it could
be indicated for OSA patients with nasal obstruction.
3.2. Causes of discontinuation
Table 1 lists the causes that led to discontinuation of OA
therapy for nonusers. This question involved 18 items, and the
respondents selected the primary cause for stopping OA
therapy. Respondents were then asked to choose any
accompanying causes for discontinuation from the same list.
If the patients selected a cause other than these items, a
detailed description was required. The most common causesTable 1 – Causes of discontinuation of OA therapy in
21 nonusers.




Bothersome to use 19.0% 38.1%
Little or no effect 19.0% 28.6%
Other reason 14.3% 23.8%
Tooth discomfort or pain 9.5% 33.3%




Gingival discomfort or pain 4.8% 14.3%
Temporomandibular
joint discomfort or pain
0.0% 9.5%
Dry mouth 0.0% 9.5%
Switched to other treatment 0.0% 9.5%
Mouthpiece came off 0.0% 4.8%
Stifling feeling 0.0% 4.8%
No reason 0.0% 4.8%
Mouthpiece breakage 0.0% 0.0%
Myofascial discomfort or pain 0.0% 0.0%
Excess salivation 0.0% 0.0%
Changes in occlusive alignment 0.0% 0.0%
Apnea dismissed 0.0% 0.0%were that the OA was ‘‘bothersome to use’’ and that the OA
had ‘‘little or no effect’’ on their sleep apnea; approximately
half of nonusers selected these items. Other frequently
occurring items included ‘‘tooth discomfort or pain’’, and
‘‘difficulty sleeping’’ with the OA. Other causes apart from the
listed items included separation from family who complained
about snoring, the effect of a new pillow, and a 16-kg weight
loss.
3.3. Complications of OA
Fig. 3 illustrates the severity of OA complications. The grade of
the complicationwas expressed numerically, then the average
for each itemwas evaluated for the representative score. All of
these complications exhibited higher scores for nonusers than
users, and significant differences were found in the scores for
‘‘difficulty sleeping’’, ‘‘stifling feeling’’, and ‘‘mouthpiece came
off’’.
3.4. Evaluation of sleep quality
Fig. 4 shows the items relating to self-evaluation of sleep
quality over the month prior to the questionnaire. OA users
recorded lower scores for ‘‘snoring’’ (loudness of snoring),
‘‘daytime sleepiness’’ and ‘‘sufficiency of sleep’’ than nonu-
sers, but there were no significant differences between these
two groups. OA users recorded significantly lower total scores
than nonusers for self-evaluation of sleep quality obtained by
adding scores for ‘‘snoring’’, ‘‘daytime sleepiness’’ and
‘‘sufficiency of sleep’’.
Fig. 5 presents the correlation of the total scores for self-
evaluation of sleep quality and follow-up ESS scores for all
patients. Spearman’s rank correlation exhibited a significant
correlation between these scores.
Fig. 6 shows the items used to evaluate sleep quality. No
significant difference was found between OA users and
nonusers for these items. There was a significant decrease
in ESS scores between the initial visit and the follow-up visit in
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the follow-up period, but the difference was not significant.4. Discussion
4.1. Respondent data
Previous studies investigating long-term OSAS treatment
reported a relatively low continuation ratio for OA therapy
[17–22]. In this study, patients who started OA therapy more
than 12 months prior to the questionnaire were investigat-
ed, and 55.5% of patients had stopped OA therapy within a
year. Because the follow-up period in our study differed
from previous studies, it was difficult to make exact
comparisons. However, the percentage of continuous OA
users and nonusers was the almost the same as in the
previous reports.
In this investigation, 50 patients did not respond to the
mailed questionnaire. One of these patients was confirmed to
have died of pancreatic cancer; thus, the patient’s death was
not likely to have been related to sleep apnea. Five patients
had moved away and did not receive the questionnaire. We
could not establish the reason for the other patient’s failure to
respond to the mailed questionnaire.
Twopatientswho responded to the questionnaire had been
treated with mono block-type OAs. Given that the structure of
mono block-type OAs is quite different from the Herbst1
appliance, we excluded these two patients’ data from the
analysis. Only the data of patients treated with Herbst1
appliances were compared.
4.2. Causes of discontinuation
In this investigation, one of the main causes for stopping OA
therapy was that the OA was ‘‘bothersome to use’’. Half of the
patients selected this reason as the cause of their discontinu-
ation when the additional question requesting a related cause
for stopping OA therapy was taken into account. Given that
‘‘bothersome to use’’ is a subjective impression, it is difficult to
cite this reason as an OA therapy complication. Because OA
therapy requires the patient to keep theOA in themouthwhile
sleeping, we presume that it is a difficult procedure to insert
the OA into themouth before sleep, and/or it is uncomfortable
to wear the OA; therefore, these patients feel that OA therapy
is ‘‘bothersome’’. Because Herbst1 appliances are composed
of two occlusal appliances connected by ametal retainer (tube
and rod), the complicated design of the appliance could
exacerbate these feelings.
Another main cause for stopping OA therapy was that
patients felt that the OA had ‘‘little or no effect’’ in preventing
sleep apnea. In general, OA therapy is recommended for mild
or moderately severe cases of sleep apnea [2,3]. However, the
average AHI of nonusers at the initial visit was more than 30,
and some of these patients should be classified as severe
cases. The average AHI of patients who cited ‘‘little or no
effect’’ for the main or related cause for stopping OA therapy
was 45.3. Fukuda et al. reported that the success rate of OA
therapy depended on the response criteria for evaluation of
treatment outcomes, and non-responders to OA therapy weremore frequently found in severeOSApatients than inmild and
moderately affected patients [23]. In addition to the AHI score,
several factors such as sleeping posture, amount of mandibu-
lar advancement, obstruction site, and craniomandibular
morphology as evaluated with lateral cephalometric radio-
graphs could predict the effectiveness of OA therapy [24].
Because we did not evaluate these objective factors except for
the pre-OA therapy AHI score, it was difficult to speculate
about the exact reasonwhy certain patients did not respond to
OA therapy. However, it is possible that those patients who
reported that OA therapy was not effective were non-
responders for OA therapy.
Typical complications of OA therapy, such as dental and/or
gingival discomfort or pain, or difficulty sleeping, were also
reported as the primary cause of discontinuation by some
patients. However, more patients discontinued OA therapy for
reasons other than the typical complications mentioned
above.
4.3. Complications of OA
The most frequent complication for nonusers was ‘‘difficulty
sleeping’’, for which a significant difference was observed
between OA users and nonusers. Significant differences were
also observed for ‘‘stifling feeling’’, and ‘‘mouthpiece came
off’’ between OA users and nonusers.
The complications listed in our questionnaire have also
been reported in previous research. The most typical and
frequent complications reported in previous research into OA
therapy were tooth and gingival pain, dry mouth, temporo-
mandibular and myofascial discomfort and excess salivation
[3–10]. In this research, these typical symptoms were found in
both OA users and nonusers, and there was no marked
difference in the prevalence of these complications. Because
the most frequent causes for stopping OA therapy were
‘‘bothersome to use’’ and ‘‘little or no effect’’, these major
complications may not have been critical issues for nonusers.
Because ‘‘difficulty sleeping’’ and ‘‘stifling feeling’’ could be
associatedwith the discomfort of keeping theOA in themouth
during sleep, this bothersome impression of the OA prevents
continuous use of the OA for these patients.
4.4. Evaluation of sleep quality
In this research, AHI at the initial visit was not significantly
different between OA users and nonusers. Given that AHI
indicates the severity of sleep apnea, we initially though that
OA users would have higher AHI scores. Because patients with
higher AHI scores should have greater motivation for
treatment, it could be speculated that these patients should
be eager to have OA therapy. However, almost 30% of the
nonusers stopped OA therapy, citing an insufficient effect on
sleep apnea, and these patients also exhibited highAHI scores.
As mentioned previously, many factors affect the effective-
ness of OA therapy, and this research could not isolate the
reason why OA therapy was ineffective in these patients.
However, this paradoxical relationship betweenAHI score and
the demand for OA therapy seems to negate a direct
association between AHI score and continuous use of OA
therapy.
[(Fig._4)TD$FIG]
Fig. 4 – Comparison of sleep quality over the month before
the questionnaire in OA users and nonusers (*p < 0.05,
Mann–Whitney U test).
[(Fig._5)TD$FIG]
Fig. 5 – Correlation of self-evaluation of sleep quality and
follow-up ESS scores for all patients. The horizontal lines
represent the total scores for self-evaluation of sleep
quality. The linear equation shows the regression line in
the scatter plots (Spearman’s rank correlation coefficient).
[(Fig._6)TD$FIG]
Fig. 6 – Comparison of sleep quality in OA users and
nonusers. A significant decrease in the ESS score was
observed in the follow-up investigation in OA users
(**p < 0.01, Wilcoxon signed-rank test).
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grade scales for ‘‘snoring’’ (loudness of snoring), ‘‘daytime
sleepiness’’ and ‘‘sufficiency of sleep’’. Since the totals of these
scores exhibited a positive correlation with follow-up ESS
scores, we suggest that these three items could have some
validity for evaluating sleep quality. The total scores of these
three items for OA users were significantly higher than those
for nonusers (Fig. 4), and the follow-up ESS scores of OA users
were significant lower than those at the initial visit. These data
suggest that OA users experience better sleep quality than
nonusers.
4.5. Limitations of this investigation
This research was based on the patients’ subjective impres-
sions of OA therapy, which were investigated with a mailedquestionnaire. This research did not evaluate objective data
except for pre-treatment AHI scores. To clarify the conditions
that promote the efficacy of and compliance with OA therapy,
further research that includes evidence from objective data
such as post-treatment AHI scores and other related factors is
required.5. Conclusion
A follow-up investigation of OSAS patients indicated that
about half of the patients stoppedOA therapy, and the average
period of OA use was 9.6 months. The main causes that led to
discontinuation of OA therapy were that the OA was
‘‘bothersome to use’’, and had ‘‘little or no effect’’ in
preventing sleep apnea. Distinctive complications for nonu-
sers were ‘‘difficulty sleeping’’ and ‘‘stifling feeling’’.Conflict of interest
The authors declare that they haveno conflicts of interestwith
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